"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A1,US 2018/0298677 A1,112-170-854-702-528,2018-10-18,2018,US 201815952198 A,2018-04-12,US 201815952198 A;;US 201762485149 P,2017-04-13,MODULAR THRESHOLD ASSEMBLY,"Disclosed is a modular threshold assembly having a frame, a cover plate detachably attached to the frame at the first end of the frame first wall and the first end of the frame second wall and an elongate body detachably attached to the frame and being proximate to the frame first wall. Also, disclosed is door frame having the modular threshold assembly. The threshold assembly can permit replacement of different components of the modular assembly, while permitting water or moisture to be expelled to the exterior.",ALKHOURY PAUL BOULOS;;TOPPAN MARCELLO,ALKHOURY PAUL BOULOS;;TOPPAN MARCELLO,VINYL WINDOW DESIGNS (2023-02-02),https://lens.org/112-170-854-702-528,Patent Application,yes,23,7,3,3,0,E06B7/14;;E06B7/14;;E06B1/70,E06B7/14;;E06B1/70;;E06B3/06,,0,0,,,,ACTIVE
2,CA,A1,CA 3001401 A1,100-679-998-397-127,2018-10-13,2018,CA 3001401 A,2018-04-13,US 201762485149 P,2017-04-13,MODULAR THRESHOLD ASSEMBLY,"Disclosed is a modular threshold assembly having a frame, a cover plate detachably attached to the frame at the first end of the frame first wall and the first end of the frame second wall and an elongate body detachably attached to the frame and being proximate to the frame first wall. Also, disclosed is door frame having the modular threshold assembly. The threshold assembly can permit replacement of different components of the modular assembly, while permitting water or moisture to be expelled to the exterior.",ALKHOURY PAUL BOULOS;;TOPPAN MARCELLO,ALKHOURY PAUL BOULOS;;TOPPAN MARCELLO,,https://lens.org/100-679-998-397-127,Patent Application,no,0,3,3,3,0,E06B7/14;;E06B7/14;;E06B1/70,E06B1/70,,0,0,,,,PENDING
3,US,B2,US 10895103 B2,086-129-626-464-083,2021-01-19,2021,US 201815952198 A,2018-04-12,US 201815952198 A;;US 201762485149 P,2017-04-13,Modular threshold assembly,"Disclosed is a modular threshold assembly having a frame, a cover plate detachably attached to the frame at the first end of the frame first wall and the first end of the frame second wall and an elongate body detachably attached to the frame and being proximate to the frame first wall. Also, disclosed is door frame having the modular threshold assembly. The threshold assembly can permit replacement of different components of the modular assembly, while permitting water or moisture to be expelled to the exterior.",ALKHOURY PAUL BOULOS;;TOPPAN MARCELLO,ALKHOURY PAUL BOULOS;;TOPPAN MARCELLO,VINYL WINDOW DESIGNS (2023-02-02),https://lens.org/086-129-626-464-083,Granted Patent,yes,30,3,3,3,0,E06B7/14;;E06B7/14;;E06B1/70,E06B7/14;;E06B1/70,,0,0,,,,ACTIVE
4,CA,A1,CA 2579234 A1,079-728-704-373-007,2008-08-20,2008,CA 2579234 A,2007-02-20,CA 2579234 A,2007-02-20,MAGNETICALLY ATTACHABLE WINDOW SCREEN SYSTEM,"A magnetically attachable window screen system comprising, a rectangular casement window comprising a casement window frame for removab ly attaching a rectangular window screen the casement window frame comprising four window frame sides, the four window frame sides comprising a lower horizontal frame side, an upp er horizontal frame side and two opposing vertical frame sides, each window frame side comprisin g a front perimeter wall and a side perimeter wall, at least one frame magnet attached to the casement window frame at least partly behind the plane defining the front perimeter wall or the plane defining the side perimeter wall, at least one support on the casement window frame for supporting the window screen, the window screen comprising a screen frame comprising four screen bars, the four screen bars comprising a lower horizontal screen bar, an upper horizontal screen ba r, and two vertical screen bars, the window screen further comprising at least one screen magnet attach ed to the window screen frame and positioned to magnetically co-operate with the at least one frame magnet attached to the casement window frame.",D UVA PASQUALINO;;ALKOURY BOULOS PAUL,D UVA PASQUALINO;;ALKOURY BOULOS PAUL,,https://lens.org/079-728-704-373-007,Patent Application,no,0,4,4,4,0,E06B9/52;;Y10S160/16;;Y10T24/32;;Y10T24/32;;E06B9/52;;Y10S160/16,E06B9/52;;A44B99/00,,0,0,,,,ACTIVE
5,CA,C,CA 2579234 C,107-407-798-821-806,2014-08-26,2014,CA 2579234 A,2007-02-20,CA 2579234 A,2007-02-20,MAGNETICALLY ATTACHABLE WINDOW SCREEN SYSTEM,"A magnetically attachable window screen system comprising, a rectangular casement window comprising a casement window frame for removably attaching a rectangular window screen the casement window frame comprising four window frame sides, the four window frame sides comprising a lower horizontal frame side, an upper horizontal frame side and two opposing vertical frame sides, each window frame side comprising a front perimeter wall and a side perimeter wall, at least one frame magnet attached to the casement window frame at least partly behind the plane defining the front perimeter wall or the plane defining the side perimeter wall, at least one support on the casement window frame for supporting the window screen, the window screen comprising a screen frame comprising four screen bars, the four screen bars comprising a lower horizontal screen bar, an upper horizontal screen bar, and two vertical screen bars, the window screen further comprising at least one screen magnet attached to the window screen frame and positioned to magnetically co-operate with the at least one frame magnet attached to the casement window frame.",ALKOURY BOULOS PAUL;;D UVA PASQUALINO,ALKOURY BOULOS PAUL;;D UVA PASQUALINO,,https://lens.org/107-407-798-821-806,Granted Patent,no,0,2,4,4,0,E06B9/52;;Y10S160/16;;Y10T24/32;;Y10T24/32;;E06B9/52;;Y10S160/16,E06B9/52;;A44B99/00,,0,0,,,,ACTIVE
6,FR,A1,FR 2798295 A1,187-311-166-654-101,2001-03-16,2001,FR 0011667 A,2000-09-13,US 39435399 A,1999-09-13,"Combined micro-macro brain stimulation lead has micro segment movable in macro segment between retracted position, deployed position extending through macro segment opening","The combined micro-macro brain stimulation lead (10) has a macro segment with an opening (50) and a micro segment (70) arranged to be movable within the macro segment between a retracted position, in which it is insider the macro segment, and a deployed position, in which it extends through the opening in the macro segment. The macro segment has at least one electrode near the opening.",MEDTRONIC INC,GIELEN FRANS LH;;BEJJANI PAUL BOULOS,,https://lens.org/187-311-166-654-101,Patent Application,no,8,3,2,12,0,A61N1/0529;;A61N1/36017;;A61N1/36025;;A61N1/36082,A61N1/05;;A61N1/36,,0,0,,,,DISCONTINUED
7,US,A1,US 2009/0183844 A1,138-454-647-768-311,2009-07-23,2009,US 7140208 A,2008-02-20,CA 2579234 A,2007-02-20,Magnetically attachable window screen system,"A magnetically attachable window screen system comprising, a rectangular casement window comprising a casement window frame for removably attaching a rectangular window screen, the casement window frame comprising four window frame sides, the four window frame sides comprising a lower horizontal frame side, an upper horizontal frame side and two opposing vertical frame sides, each window frame side comprising a front perimeter wall and a side perimeter wall, at least one frame magnet attached to the casement window frame at least partly behind the plane defining the front perimeter wall or the plane defining the side perimeter wall, at least one support on the casement window frame for supporting the window screen, the window screen comprising a screen frame comprising four screen bars, the four screen bars comprising a lower horizontal screen bar, an upper horizontal screen bar, and two vertical screen bars, the window screen further comprising at least one screen magnet attached to the window screen frame and positioned to magnetically co-operate with the at least one frame magnet attached to the casement window frame.",ALKHOURY BOULOS PAUL;;D UVA PASQUALINO,ALKHOURY BOULOS PAUL;;D UVA PASQUALINO,,https://lens.org/138-454-647-768-311,Patent Application,yes,34,17,4,4,0,E06B9/52;;Y10S160/16;;Y10T24/32;;Y10T24/32;;E06B9/52;;Y10S160/16,E06B3/00;;A44B99/00,160/369;;24/303,0,0,,,,ACTIVE
8,US,B2,US 8037923 B2,113-552-654-286-785,2011-10-18,2011,US 7140208 A,2008-02-20,CA 2579234 A,2007-02-20,Magnetically attachable window screen system,"A magnetically attachable window screen system comprising, a rectangular casement window comprising a casement window frame for removably attaching a rectangular window screen, the casement window frame comprising four window frame sides, the four window frame sides comprising a lower horizontal frame side, an upper horizontal frame side and two opposing vertical frame sides, each window frame side comprising a front perimeter wall and a side perimeter wall, at least one frame magnet attached to the casement window frame at least partly behind the plane defining the front perimeter wall or the plane defining the side perimeter wall, at least one support on the casement window frame for supporting the window screen, the window screen comprising a screen frame comprising four screen bars, the four screen bars comprising a lower horizontal screen bar, an upper horizontal screen bar, and two vertical screen bars, the window screen further comprising at least one screen magnet attached to the window screen frame and positioned to magnetically co-operate with the at least one frame magnet attached to the casement window frame.",ALKHOURY BOULOS PAUL;;D UVA PASQUALINO,ALKHOURY BOULOS PAUL;;D UVA PASQUALINO,,https://lens.org/113-552-654-286-785,Granted Patent,yes,35,19,4,4,0,E06B9/52;;Y10S160/16;;Y10T24/32;;Y10T24/32;;E06B9/52;;Y10S160/16,E06B9/52;;A44B99/00,160/369;;X160DIG 16,0,0,,,,ACTIVE
9,CA,A1,CA 2584090 A1,141-500-919-323-918,2008-10-04,2008,CA 2584090 A,2007-04-04,CA 2584090 A,2007-04-04,"WINDOW CLADDING DEVICE, METHOD AND SYSTEM","A strip of cladding covering an exterior window frame or mullion and joints between the frame or mullion and the surfaces of the adjacent window panes. The strip has a cover with first and second longitudinal opposing sides for placement over the frame or mullion and at least one joint. The first side has a first seal running substantially parallel to the longitudinal axi s of the cover for sealing the cover to the exterior surface of a window pane. The second side has a second seal running substantially parallel to the longitudinal axis of the cover for sealing the cover to the frame or another window pane. The cover is attachable to the frame or mullion for sealing the frame and adjacent joint or mullion and adjacent joints between the first seal and the second seal, in a substantially water resistant manner.",ALKOURY BOULOS PAUL;;KOZLOWSKI CHRISTOPHER H,ALKOURY BOULOS PAUL;;KOZLOWSKI CHRISTOPHER H,,https://lens.org/141-500-919-323-918,Patent Application,no,0,0,2,2,0,E06B3/302;;E06B7/16;;E06B3/302;;E06B7/16,E06B7/26;;E06B3/30;;E06B7/14;;E06B7/16,,0,0,,,,DISCONTINUED
10,US,A1,US 2001/0014820 A1,029-230-193-373-096,2001-08-16,2001,US 81885401 A,2001-03-28,US 81885401 A;;US 39435399 A;;US 924798 A,1998-01-20,Method of stimulating brain tissue using combined micro-macro brain stimulation lead,"
   A lead for brain stimulation comprising a macro segment having a macro electrode for test stimulation and subsequent chronic stimulation, and a micro segment having a micro electrode for single cell recording is described. Methods for using the lead to stimulate brain tissue and to identify functional boundaries within brain tissue are also provided. 
",MEDTRONIC INC,GIELEN FRANS L H;;BEJJANI PAUL BOULOS,,https://lens.org/029-230-193-373-096,Patent Application,yes,0,45,4,12,0,A61N1/0529;;A61N1/0534;;A61N1/3605;;A61N1/36082;;A61N1/0529;;A61N1/36082;;A61N1/0534;;A61N1/3605,A61N1/05;;A61N1/36,607/116,0,0,,,,DISCONTINUED
11,DE,A1,DE 10044115 A1,172-434-570-496-112,2001-04-12,2001,DE 10044115 A,2000-09-07,US 39435399 A,1999-09-13,Kombinierte Mikro-Makro-Hirnstimulationsleitung und Verfahren zu deren Verwendung,"Eine Leitung für Hirnstimulation mit einem Makro-Segment, welches eine Makro-Elektrode für eine Test-Stimulation und anschließende Dauerstimulation aufweist, und mit einem Mikro-Segment, welches eine Mikro-Elektrode für Einzelzellaufzeichnung aufweist, wird beschrieben. Verfahren zum Verwenden der Leitung zum Stimulieren von Hirngewebe und zum Identifizieren funktionaler Grenzen innerhalb des Hirngewebes werden ebenfalls angegeben.",MEDTRONIC INC,GIELEN FRANS L H;;BEJJANI PAUL BOULOS,,https://lens.org/172-434-570-496-112,Patent Application,no,0,9,2,12,0,A61N1/0529;;A61N1/36017;;A61N1/36025;;A61N1/36082,A61N1/05;;A61N1/36,,0,0,,,,DISCONTINUED
12,US,A1,US 2002/0022872 A1,128-082-438-381-359,2002-02-21,2002,US 94740101 A,2001-09-07,US 94740101 A;;US 39435399 A;;US 924798 A,1998-01-20,Combined micro-macro brain stimulation lead and method of using same,"
   A lead for brain stimulation comprising a macro segment having a macro electrode for test stimulation and subsequent chronic stimulation, and a micro segment having a micro electrode for single cell recording is described. Methods for using the lead to stimulate brain tissue and to identify functional boundaries within brain tissue are also provided. 
",MEDTRONIC INC,GIELEN FRANS L H;;BEJJANI PAUL BOULOS,,https://lens.org/128-082-438-381-359,Patent Application,yes,0,39,4,12,0,A61N1/0529;;A61N1/0534;;A61N1/3605;;A61N1/36082;;A61N1/0529;;A61N1/36082;;A61N1/0534;;A61N1/3605,A61N1/05;;A61N1/36,607/116,0,0,,,,DISCONTINUED
13,US,A1,US 2001/0027336 A1,154-229-622-992-391,2001-10-04,2001,US 81859001 A,2001-03-28,US 81859001 A;;US 39435399 A;;US 924798 A,1998-01-20,Combined micro-macro brain stimulation system,"
   A lead for brain stimulation comprising a macro segment having a macro electrode for test stimulation and subsequent chronic stimulation, and a micro segment having a micro electrode for single cell recording is described. Methods for using the lead to stimulate brain tissue and to identify functional boundaries within brain tissue are also provided. 
",MEDTRONIC INC,GIELEN FRANS L H;;BEJJANI PAUL BOULOS,,https://lens.org/154-229-622-992-391,Patent Application,yes,0,69,4,12,0,A61N1/0529;;A61N1/0534;;A61N1/3605;;A61N1/36082;;A61N1/0529;;A61N1/36082;;A61N1/0534;;A61N1/3605,A61N1/05;;A61N1/36,607/116,0,0,,,,DISCONTINUED
14,US,A1,US 2001/0016765 A1,151-363-108-084-831,2001-08-23,2001,US 81858901 A,2001-03-28,US 81858901 A;;US 39435399 A;;US 924798 A,1998-01-20,Method of Identifying Functional Boundaries Between Brain Structures,"
   A lead for brain stimulation comprising a macro segment having a macro electrode for test stimulation and subsequent chronic stimulation, and a micro segment having a micro electrode for single cell recording is described. Methods for using the lead to stimulate brain tissue and to identify functional boundaries within brain tissue are also provided. 
",MEDTRONIC INC,GIELEN FRANS L H;;BEJJANI PAUL BOULOS,,https://lens.org/151-363-108-084-831,Patent Application,yes,0,17,4,12,0,A61N1/0529;;A61N1/0534;;A61N1/3605;;A61N1/36082;;A61N1/0529;;A61N1/36082;;A61N1/0534;;A61N1/3605,A61N1/05;;A61N1/36,607/116,0,0,,,,DISCONTINUED
15,US,B1,US 6691761 B1,010-178-503-410-126,2004-02-17,2004,US 13640802 A,2002-05-02,US 13640802 A,2002-05-02,Roll up screen edge control,"
    A rolled screen for a screen opening which may be part of a casement window frame unwinds to close the screen opening. The extended lateral edges of said screen pass through lateral slots and the screen is shaped or treated to prevent the movement of edges inwardly through the slots. 
",VIPER PROFILE LTD,ALKHOURY BOULOS PAUL;;D UVA PASQUALINO;;GRASSI ARTURO;;SPATAFORA PHILIP,VIPER PROFILE LIMITED (2002-04-22),https://lens.org/010-178-503-410-126,Granted Patent,yes,4,75,1,1,0,E06B9/54;;E06B9/581;;E06B9/54;;E06B9/581,E06B9/54;;E06B9/58,160/273.1;;160/98,0,0,,,,EXPIRED
16,US,A1,US 2008/0148346 A1,076-730-245-733-192,2008-06-19,2008,US 85591407 A,2007-09-14,US 85591407 A;;US 87502406 P,2006-12-15,COMPLIANCE CONTROL SYSTEM,"A method comprises automatically obtaining network data, and automatically processing the network data to detect violation of a compliance control policy of an entity.",GILL RAVINDER;;COOPER LEE;;YOUNG PAUL;;SRIVASTAVA PANKAJ;;AOUN BOULOS,GILL RAVINDER;;COOPER LEE;;YOUNG PAUL;;SRIVASTAVA PANKAJ;;AOUN BOULOS,CISCO TECHNOLOGY INC (2010-09-29);;SAP AG (2007-01-17),https://lens.org/076-730-245-733-192,Patent Application,yes,2,62,1,1,0,H04L63/1408;;H04L63/1408;;H04L63/20;;H04L63/20,H04L9/00,726/1,0,0,,,,DISCONTINUED
17,US,A1,US 2005/0153177 A1,071-801-787-544-349,2005-07-14,2005,US 96460504 A,2004-10-15,US 96460504 A;;US 51108303 P,2003-10-15,Solid electrolyte fuel cell supported by an integrated reformer,"The present invention relates to a solid oxide fuel cell comprising a reformer for supporting the solid oxide fuel cell, an anode, an electrolyte, and a cathode. The reformer includes an electroconductive mixture of active material and a polymeric ceramic material shaped to constitute a slab having an upper surface and a lower surface and grooves along at least one of the upper surface and the lower surface and flat regions along the periphery of the grooved surface.",GITZHOFER FRANCOIS;;LASIA ANDRZEJ;;ABATZOGLOU NICOLAS;;ROWNTREE PAUL;;JUREWICZ JERZY;;BRISARD GESSIE;;MENARD HUGUES;;BOULOS MAHER,GITZHOFER FRANCOIS;;LASIA ANDRZEJ;;ABATZOGLOU NICOLAS;;ROWNTREE PAUL;;JUREWICZ JERZY;;BRISARD GESSIE;;MENARD HUGUES;;BOULOS MAHER,UNIVERSITÉ DE SHERBROOKE (2005-03-16);;SOCIETE DE COMMERCIALISATION DES PRODUITS DE LA RECHERCHE APPLIQUEE SOCPRA SCIENCES ET GENIE S.E.C (2007-08-30),https://lens.org/071-801-787-544-349,Patent Application,yes,29,3,3,3,0,B01J19/249;;B01J19/249;;B01J2219/2453;;B01J2219/2453;;B01J2219/2459;;B01J2219/2459;;B01J2219/247;;B01J2219/247;;B01J2219/2482;;B01J2219/2482;;B01J2219/2487;;B01J2219/2487;;B01J2219/249;;B01J2219/249;;B01J2219/2493;;B01J2219/2493;;C01B3/02;;C01B3/02;;C01B2203/02;;C01B2203/02;;C01B2203/067;;C01B2203/067;;H01M8/0612;;H01M8/0612;;H01M8/1231;;H01M8/1231;;Y02E60/50;;Y02E60/50,B01J19/00;;B01J19/24;;B05D5/12;;C01B3/02;;H01M4/90;;H01M8/02;;H01M8/06;;H01M8/12,429/19;;429/40;;427/115;;422/240,0,0,,,,INACTIVE
18,US,B2,US 7670703 B2,111-750-362-604-870,2010-03-02,2010,US 96460504 A,2004-10-15,US 96460504 A;;US 51108303 P,2003-10-15,Solid electrolyte fuel cell supported by an integrated reformer,"The solid oxide fuel cell can comprise: an electroconductive and porous reformer including a catalytically active material and shaped to constitute a solid slab having a first surface and a second surface opposite the first surface, and a plurality of adjacent grooves along the first surface, and flat regions adjacent the plurality of grooves; an anode layer covering the plurality of grooves of the reformer slab and having a corresponding grooved shape; an electrolyte layer covering the anode layer over the plurality of grooves of the reformer slab and having a corresponding grooved shape, and extending over the flat regions; and a cathode layer covering the electrolyte layer over the grooves of the reformer slab and having a corresponding grooved shape.",COMMERCIALISATION DES PRODUITS,GITZHOFER FRANCOIS;;LASIA ANDRZEJ;;ABATZOGLOU NICOLAS;;ROWNTREE PAUL;;JUREWICZ JERZY;;BRISARD GESSIE;;MENARD HUGUES;;BOULOS MAHER,UNIVERSITÉ DE SHERBROOKE (2005-03-16);;SOCIETE DE COMMERCIALISATION DES PRODUITS DE LA RECHERCHE APPLIQUEE SOCPRA SCIENCES ET GENIE S.E.C (2007-08-30),https://lens.org/111-750-362-604-870,Granted Patent,yes,29,0,3,3,0,B01J19/249;;B01J19/249;;B01J2219/2453;;B01J2219/2453;;B01J2219/2459;;B01J2219/2459;;B01J2219/247;;B01J2219/247;;B01J2219/2482;;B01J2219/2482;;B01J2219/2487;;B01J2219/2487;;B01J2219/249;;B01J2219/249;;B01J2219/2493;;B01J2219/2493;;C01B3/02;;C01B3/02;;C01B2203/02;;C01B2203/02;;C01B2203/067;;C01B2203/067;;H01M8/0612;;H01M8/0612;;H01M8/1231;;H01M8/1231;;Y02E60/50;;Y02E60/50,H01M8/10;;B01J19/00;;B01J19/24;;B05D5/12;;C01B3/02;;H01M4/90;;H01M8/02;;H01M8/06;;H01M8/12,429/30;;429/34;;429/40;;429/19;;427/115,2,0,,,"Vernoux, P. Guindet, J., Gehain, E. and M. Kleitz, ""Catalysts for Continuous Methane Reforming in Medium Temperature SOFC"", Electrochemical Proceedings, V. 97-18, 219-227.;;Huh, Chao Yi and M. Farooque, ""Carbonate Fuel Cell Materials"", Advanced Materials & Processes, Jul. 2002, 31-34.",INACTIVE
19,CA,A1,CA 2484919 A1,115-277-962-792-769,2005-04-15,2005,CA 2484919 A,2004-10-15,US 51108303 P,2003-10-15,SOLID ELECTROLYTE FUEL CELL SUPPORTED BY AN INTEGRATED REFORMER,"The present invention relates to a solid oxide fuel cell comprising a reformer for supporting the solid oxide fuel cell, an anode, an electrolyte, and a cathode. The reformer includes an electroconductive mixture of active materi al and a polymeric ceramic material shaped to constitute a slab having an upper surface and a lower surface and grooves along at least one of the upper surface and the lower surface and flat regions along the periphery of the grooved surface.",UNIV SHERBROOKE,ROWNTREE PAUL;;BRISARD GESSIE;;BOULOS MAHER;;MENARD HUGUES;;ABATZOGLOU NICOLAS;;LASIA ANDRZEJ;;JUREWICZ JERZY;;GITZHOFER FRANCOIS,,https://lens.org/115-277-962-792-769,Patent Application,no,0,2,3,3,0,B01J19/249;;B01J19/249;;B01J2219/2453;;B01J2219/2453;;B01J2219/2459;;B01J2219/2459;;B01J2219/247;;B01J2219/247;;B01J2219/2482;;B01J2219/2482;;B01J2219/2487;;B01J2219/2487;;B01J2219/249;;B01J2219/249;;B01J2219/2493;;B01J2219/2493;;C01B3/02;;C01B3/02;;C01B2203/02;;C01B2203/02;;C01B2203/067;;C01B2203/067;;H01M8/0612;;H01M8/0612;;H01M8/1231;;H01M8/1231;;Y02E60/50;;Y02E60/50,B01J19/00;;B01J19/24;;B05D5/12;;C01B3/02;;H01M4/90;;H01M8/02;;H01M8/06;;H01M8/12,,0,0,,,,DISCONTINUED
20,EP,A4,EP 3890553 A4,137-865-628-214-276,2022-08-03,2022,EP 19892876 A,2019-12-06,US 201862776620 P;;US 201962816735 P;;US 2019/0065042 W,2018-12-07,ORAL CARE SYSTEM AND PACKAGING,,SAGE PRODUCTS LLC,FOWLER PAUL M;;CAGLE RONALD C;;SEBASTIAN THERESA L;;RAPINCHUK TIMOTHY J;;BOULOS CATHERINE S;;PATEL ABHI R,,https://lens.org/137-865-628-214-276,Search Report,no,0,0,9,9,0,A45D44/18;;A46B9/04;;A46B11/001;;A46B5/021;;A46B17/02;;A45D44/18;;A46B5/021;;A46B17/02,A46B11/00;;A45D44/18;;A46B15/00;;A47K5/18,,1,0,,,No further relevant documents disclosed,PENDING
21,CA,A1,CA 3122269 A1,002-293-119-379-068,2020-06-11,2020,CA 3122269 A,2019-12-06,US 201862776620 P;;US 201962816735 P;;US 2019/0065042 W,2018-12-07,ORAL CARE SYSTEM AND PACKAGING,"An oral care regimen kit includes a packaging unit. The packaging unit includes an oral care system, which includes a toothbrush and an oral fluid container, and a clip configured to engage a first portion of the oral care system such that the toothbrush cannot be depressed into the oral fluid container while the oral care system is engaged by the clip.",SAGE PRODUCTS LLC,FOWLER PAUL M;;CAGLE RONALD C;;SEBASTIAN THERESA L;;RAPINCHUK TIMOTHY J;;BOULOS CATHERINE S;;PATEL ABHI R,,https://lens.org/002-293-119-379-068,Patent Application,no,0,0,9,9,0,A45D44/18;;A46B9/04;;A46B11/001;;A46B5/021;;A46B17/02;;A45D44/18;;A46B5/021;;A46B17/02,A46B11/00;;A45D44/18;;A46B15/00;;A47K5/18,,0,0,,,,PENDING
22,AU,B2,AU 2019/391124 B2,157-633-373-004-949,2023-01-19,2023,AU 2019/391124 A,2019-12-06,US 201862776620 P;;US 201962816735 P;;US 2019/0065042 W,2018-12-07,Oral care system and packaging,"An oral care regimen kit includes a packaging unit. The packaging unit includes an oral care system, which includes a toothbrush and an oral fluid container, and a clip configured to engage a first portion of the oral care system such that the toothbrush cannot be depressed into the oral fluid container while the oral care system is engaged by the clip.",SAGE PRODUCTS LLC,FOWLER PAUL M;;CAGLE RONALD C;;SEBASTIAN THERESA L;;RAPINCHUK TIMOTHY J;;BOULOS CATHERINE S;;PATEL ABHI R,,https://lens.org/157-633-373-004-949,Granted Patent,no,4,0,9,9,0,A45D44/18;;A46B9/04;;A46B11/001;;A46B5/021;;A46B17/02;;A45D44/18;;A46B5/021;;A46B17/02,A46B11/00;;A45D44/18;;A46B15/00;;A47K5/18,,0,0,,,,ACTIVE
23,US,A1,US 2022/0015526 A1,032-502-769-541-641,2022-01-20,2022,US 201917311012 A,2019-12-06,US 201917311012 A;;US 201862776620 P;;US 201962816735 P;;US 2019/0065042 W,2018-12-07,ORAL CARE SYSTEM AND PACKAGING,"An oral care regimen kit includes a packaging unit. The packaging unit includes an oral care system, which includes a toothbrush and an oral fluid container, and a clip configured to engage a first portion of the oral care system such that the toothbrush cannot be depressed into the oral fluid container while the oral care system is engaged by the clip.",SAGE PRODUCTS LLC,FOWLER PAUL M;;CAGLE RONALD C;;SEBASTIAN THERESA L;;RAPINCHUK TIMOTHY J;;BOULOS CATHERINE S;;PATEL ABHI R,SAGE PRODUCTS LLC (2021-08-27),https://lens.org/032-502-769-541-641,Patent Application,yes,0,1,9,9,0,A45D44/18;;A46B9/04;;A46B11/001;;A46B5/021;;A46B17/02;;A45D44/18;;A46B5/021;;A46B17/02,A45D44/18;;A46B17/02,,0,0,,,,PENDING
24,US,S,US D0988868 S,077-131-651-211-64X,2023-06-13,2023,US 201929683163 F,2019-03-11,US 201929683163 F,2019-03-11,Packaging for oral care device,,SAGE PRODUCTS LLC,FOWLER PAUL M;;CAGLE RONALD C;;SEBASTIAN THERESA L;;RAPINCHUK TIMOTHY J;;BOULOS CATHERINE S;;PATEL ABHI R,SAGE PRODUCTS LLC (2019-04-02),https://lens.org/077-131-651-211-64X,Design Right,no,90,0,5,5,0,,,0907;;D 9456;;D9/457,9,0,,,"International Search Report and Written Opinion for International Application No. PCT/US2019/065042, dated Apr. 7, 2020, 11 pages.;;Invitation to Pay Additional Fees for International Application No. PCT/US2019/065042, dated Feb. 10, 2020, 2 pages.;;PCT Collaborative Search and Examination Pilot, Peer ISA China National Intellectual Property, International Search Report and Written Opinion for International Application No. PCT/US2019/065042, completed Feb. 28, 2020, 13 pages.;;PCT Collaborative Search and Examination Pilot, Peer ISA European Patent Office, International Search Report and Written Opinion for International Application No. PCT/US2019/065042, completed Feb. 18, 2020, 10 pages.;;PCT Collaborative Search and Examination Pilot, Peer ISA Japan Patent Office, International Search Report and Written Opinion for International Application No. PCT/US2019/065042, completed Mar. 4, 2020, 9 pages.;;PCT Collaborative Search and Examination Pilot, Peer ISA Korean Intellectual Property Office, International Search Report and Written Opinion for International Application No. PCT/US2019/065042, completed Mar. 6, 2020, 16 pages.;;Translation of KR 10-2009-0133048 A; provided by International Searching Authority for International Search Report and Written Opinion of International Application No. PCT/US2019/065042, dated Apr. 7, 2020, 4 pages.;;Pharmacy Counter Space Cardboard Display Box For Medicine Drugs. [online] Published on Sep. 22, 2018. Retrieved Jan. 3, 2020 from URL: http://www.cardboardpalletdisplay.com/sale-6122822-pharmacy-counter-space-cardboard-display-box-for-medicine-drugs.html.;;Sage Self Oral Care Toothbrush. [online] Published on Nov. 30, 2019. Retrieved Jan. 3, 2020 from URL: https://www.stryker.com/us/en/sage/products/sage-self-oral-care.html.",ACTIVE
25,EP,A1,EP 3890553 A1,115-493-970-742-32X,2021-10-13,2021,EP 19892876 A,2019-12-06,US 201862776620 P;;US 201962816735 P;;US 2019/0065042 W,2018-12-07,ORAL CARE SYSTEM AND PACKAGING,,SAGE PRODUCTS LLC,FOWLER PAUL M;;CAGLE RONALD C;;SEBASTIAN THERESA L;;RAPINCHUK TIMOTHY J;;BOULOS CATHERINE S;;PATEL ABHI R,,https://lens.org/115-493-970-742-32X,Patent Application,yes,0,0,9,9,0,A45D44/18;;A46B9/04;;A46B11/001;;A46B5/021;;A46B17/02;;A45D44/18;;A46B5/021;;A46B17/02,A46B11/00;;A45D44/18;;A46B15/00;;A47K5/18,,0,0,,,,PENDING
26,AU,A1,AU 2019/391124 A1,177-996-843-129-155,2021-07-15,2021,AU 2019/391124 A,2019-12-06,US 201862776620 P;;US 201962816735 P;;US 2019/0065042 W,2018-12-07,Oral care system and packaging,"An oral care regimen kit includes a packaging unit. The packaging unit includes an oral care system, which includes a toothbrush and an oral fluid container, and a clip configured to engage a first portion of the oral care system such that the toothbrush cannot be depressed into the oral fluid container while the oral care system is engaged by the clip.",SAGE PRODUCTS LLC,FOWLER PAUL M;;CAGLE RONALD C;;SEBASTIAN THERESA L;;RAPINCHUK TIMOTHY J;;BOULOS CATHERINE S;;PATEL ABHI R,,https://lens.org/177-996-843-129-155,Patent Application,no,0,0,9,9,0,A45D44/18;;A46B9/04;;A46B11/001;;A46B5/021;;A46B17/02;;A45D44/18;;A46B5/021;;A46B17/02,A46B11/00;;A45D44/18;;A46B15/00;;A47K5/18,,0,0,,,,ACTIVE
27,AU,A1,AU 2023/202391 A1,194-638-341-579-910,2023-05-11,2023,AU 2023/202391 A,2023-04-19,AU 2023/202391 A;;AU 2019/391124 A;;US 201862776620 P;;US 201962816735 P;;US 2019/0065042 W,2018-12-07,Oral care system and packaging,"An oral care regimen kit includes a packaging unit. The packaging unit includes an oral care system, which includes a toothbrush and an oral fluid container, and a clip configured to engage a first portion of the oral care system such that the toothbrush cannot be depressed into the oral fluid container while the oral care system is engaged by the clip.",SAGE PRODUCTS LLC,FOWLER PAUL M;;CAGLE RONALD C;;SEBASTIAN THERESA L;;RAPINCHUK TIMOTHY J;;BOULOS CATHERINE S;;PATEL ABHI R,,https://lens.org/194-638-341-579-910,Patent Application,no,0,0,9,9,0,A45D44/18;;A46B9/04;;A46B11/001;;A46B5/021;;A46B17/02;;A45D44/18;;A46B5/021;;A46B17/02,A46B11/00;;A45D44/18;;A46B15/00;;A47K5/18,,0,0,,,,PENDING
28,WO,A1,WO 2020/118235 A1,029-904-951-359-858,2020-06-11,2020,US 2019/0065042 W,2019-12-06,US 201862776620 P;;US 201962816735 P,2018-12-07,ORAL CARE SYSTEM AND PACKAGING,"An oral care regimen kit includes a packaging unit. The packaging unit includes an oral care system, which includes a toothbrush and an oral fluid container, and a clip configured to engage a first portion of the oral care system such that the toothbrush cannot be depressed into the oral fluid container while the oral care system is engaged by the clip.",SAGE PRODUCTS LLC,FOWLER PAUL M;;CAGLE RONALD C;;SEBASTIAN THERESA L;;RAPINCHUK TIMOTHY J;;BOULOS CATHERINE S;;PATEL ABHI R,,https://lens.org/029-904-951-359-858,Patent Application,yes,10,3,9,9,0,A45D44/18;;A46B9/04;;A46B11/001;;A46B5/021;;A46B17/02;;A45D44/18;;A46B5/021;;A46B17/02,A46B11/00;;A45D44/18;;A46B15/00;;A47K5/18,,1,0,,,See also references of EP 3890553A4,PENDING
29,US,A1,US 2006/0031023 A1,013-303-150-739-872,2006-02-09,2006,US 24632505 A,2005-10-06,US 24632505 A;;US 29307602 A;;US 33857801 P,2001-11-13,Mass intensity profiling system and uses thereof,"The present invention is directed to computer automated methods and systems for identifying and characterizing biomolecules in a biological sample. Mass spectrometry measurements are obtained on biomolecules in a sample. These measurements are analyzed to determine the abundance of the biomolecules in the sample, and the abundance measurements are coupled with one or more distinguishing characteristics of biomolecules they are associated with, thereby permitting computer-mediated comparison of abundances of biomolecules from multiple biological samples.",CAPRION PHARMACEUTICALS,AGUILERA FRANK R M;;FAUBERT DENIS;;BOULOS MARGUERITE;;TSANG JOHN S;;HU MICHAEL;;OSTERMANN JOACHIM B;;KEARNEY PAUL E;;THIBAULT PIERRE,CAPRION PHARMACEUTICALS INC (2002-12-17),https://lens.org/013-303-150-739-872,Patent Application,yes,10,1,9,9,0,G01N33/6848;;G01N33/6848;;Y10T436/24;;Y10T436/24,G01N27/62;;G06F19/00;;B01J20/283;;G01N30/26;;G01N30/34;;G01N30/72;;G01N30/88;;G01N33/48;;G01N33/50;;G01N33/68,702/19,0,0,,,,DISCONTINUED
30,US,A1,US 2006/0003385 A1,178-035-061-076-187,2006-01-05,2006,US 18895405 A,2005-07-25,US 18895405 A;;US 29307602 A;;US 33857801 P,2001-11-13,Mass intensity profiling system and uses thereof,"The present invention is directed to computer automated methods and systems for identifying and characterizing biomolecules in a biological sample. Mass spectrometry measurements are obtained on biomolecules in a sample. These measurements are analyzed to determine the abundance of the biomolecules in the sample, and the abundance measurements are coupled with one or more distinguishing characteristics of biomolecules they are associated with, thereby permitting computer-mediated comparison of abundances of biomolecules from multiple biological samples.",CAPRION PHARMACEUTICALS,AGUILERA FRANK R M;;FAUBERT DENIS;;BOULOS MARGUERITE;;TSANG JOHN S;;HU MICHAEL;;OSTERMANN JOACHIM B;;KEARNEY PAUL E;;THIBAULT PIERRE,CAPRION PHARMACEUTICALS INC (2002-12-17),https://lens.org/178-035-061-076-187,Patent Application,yes,13,12,9,9,0,G01N33/6848;;G01N33/6848;;Y10T436/24;;Y10T436/24,C12Q1/68;;G01N27/62;;B01J20/283;;G01N30/26;;G01N30/34;;G01N30/72;;G01N30/88;;G01N33/48;;G01N33/53;;G01N33/68;;G06F19/00,435/7.1;;702/19;;436/86,0,0,,,,DISCONTINUED
31,US,A1,US 2006/0269944 A1,149-704-007-269-328,2006-11-30,2006,US 42911306 A,2006-05-04,US 42911306 A;;US 29307602 A;;US 33857801 P,2001-11-13,Mass Intensity profiling system and uses thereof,"The present invention is directed to computer automated methods and systems for identifying and characterizing biomolecules in a biological sample. Mass spectrometry measurements are obtained on biomolecules in a sample. These measurements are analyzed to determine the abundance of the biomolecules in the sample, and the abundance measurements are coupled with one or more distinguishing characteristics of biomolecules they are associated with, thereby permitting computer-mediated comparison of abundances of biomolecules from multiple biological samples.",AGUILERA FRANK R M;;FAUBERT DENIS;;BOULOS MARGUERITE;;TSANG JOHN S;;HU MICHAEL;;OSTERMANN JOACHIM B;;KEARNEY PAUL E;;THIBAULT PIERRE,AGUILERA FRANK R M;;FAUBERT DENIS;;BOULOS MARGUERITE;;TSANG JOHN S;;HU MICHAEL;;OSTERMANN JOACHIM B;;KEARNEY PAUL E;;THIBAULT PIERRE,CAPRION PHARMACEUTICALS INC (2002-12-17),https://lens.org/149-704-007-269-328,Patent Application,yes,11,2,9,9,0,G01N33/6848;;G01N33/6848;;Y10T436/24;;Y10T436/24,C12Q1/68;;G01N27/62;;B01J20/283;;G01N30/26;;G01N30/34;;G01N30/72;;G01N30/88;;G01N33/48;;G01N33/68;;G06F19/00,435/6;;702/19;;702/20;;436/86,0,0,,,,DISCONTINUED
32,WO,A3,WO 2003/042774 A3,016-571-267-217-613,2003-12-18,2003,IB 0205827 W,2002-11-13,US 33857801 P,2001-11-13,MASS INTENSITY PROFILING SYSTEM AND USES THEREOF,"The present invention is directed to computer automated methods and systems for identifying and characterizing biomolecules in a biological sample&period; Mass spectrometry measurements are obtained on biomolecules in a sample&period; These measurements are analyzed to determine the abundance of the biomolecules in the sample, and the abundance measurements are couple with one or more distinguishing characteristics of biomolecules they are associated with, thereby permitting computerᇁmediated comparison of abundances of biomolecules from multiple biological samples&period;",CAPRION PHARMACEUTICALS INC,AGUILERA FRANK REINALDO MORALE;;FAUBERT DENIS;;BOULOS MARGUERITE;;TSANG JOHN SHING-CHUN;;HU MICHAEL;;OSTERMANN JOACHIM BERNHARD;;KEARNEY PAUL EDWARD;;THIBAULT PIERRE,,https://lens.org/016-571-267-217-613,Search Report,yes,1,0,9,9,0,G01N33/6848;;G01N33/6848;;Y10T436/24;;Y10T436/24,G01N27/62;;B01J20/283;;G01N30/26;;G01N30/34;;G01N30/72;;G01N30/88;;G01N33/48;;G01N33/68,,2,2,118-946-632-838-693;;114-873-916-473-243,10404161;;10.1038/10890;;8081066,"LINK A J ET AL: ""Direct analysis of protein complexes using mass spectrometry"", NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 17, July 1999 (1999-07-01), pages 676 - 682, XP002184653, ISSN: 1087-0156;;COTTRELL J S: ""PROTEIN IDENTIFICATION BY PEPTIDE MASS FINGERPRINTING"", PEPTIDE RESEARCH, NATICK, MA, US, vol. 7, no. 3, 1994, pages 115 - 124, XP002932021, ISSN: 1040-5704",PENDING
33,US,A1,US 2003/0129760 A1,016-964-997-061-70X,2003-07-10,2003,US 29307602 A,2002-11-13,US 29307602 A;;US 33857801 P,2001-11-13,Mass intensity profiling system and uses thereof,"
   The present invention is directed to computer automated methods and systems for identifying and characterizing biomolecules in a biological sample. Mass spectrometry measurements are obtained on biomolecules in a sample. These measurements are analyzed to determine the abundance of the biomolecules in the sample, and the abundance measurements are coupled with one or more distinguishing characteristics of biomolecules they are associated with, thereby permitting computer-mediated comparison of abundances of biomolecules from multiple biological samples. 
",AGUILERA FRANK REINALDO MORALES;;FAUBERT DENIS;;BOULOS MARGUERITE;;TSANG JOHN SHING-CHUN;;HU MICHAEL;;OSTERMANN JOACHIM BERNHARD;;KEARNEY PAUL EDWARD;;THIBAULT PIERRE,AGUILERA FRANK REINALDO MORALE;;FAUBERT DENIS;;BOULOS MARGUERITE;;TSANG JOHN SHING-CHUN;;HU MICHAEL;;OSTERMANN JOACHIM BERNHARD;;KEARNEY PAUL EDWARD;;THIBAULT PIERRE,CAPRION PHARMACEUTICALS INC (2002-12-17),https://lens.org/016-964-997-061-70X,Patent Application,yes,12,32,9,9,0,G01N33/6848;;G01N33/6848;;Y10T436/24;;Y10T436/24,G01N27/62;;B01J20/283;;G01N30/26;;G01N30/34;;G01N30/72;;G01N30/88;;G01N33/48;;G01N33/68,436/86;;702/19;;702/27;;436/173,0,0,,,,DISCONTINUED
34,WO,A2,WO 2003/042774 A2,139-037-609-554-186,2003-05-22,2003,IB 0205827 W,2002-11-13,US 33857801 P,2001-11-13,MASS INTENSITY PROFILING SYSTEM AND USES THEREOF,"The present invention is directed to computer automated methods and systems for identifying and characterizing biomolecules in a biological sample&period; Mass spectrometry measurements are obtained on biomolecules in a sample&period; These measurements are analyzed to determine the abundance of the biomolecules in the sample, and the abundance measurements are couple with one or more distinguishing characteristics of biomolecules they are associated with, thereby permitting computerᇁmediated comparison of abundances of biomolecules from multiple biological samples&period;",CAPRION PHARMACEUTICALS INC,AGUILERA FRANK REINALDO MORALE;;FAUBERT DENIS;;BOULOS MARGUERITE;;TSANG JOHN SHING-CHUN;;HU MICHAEL;;OSTERMANN JOACHIM BERNHARD;;KEARNEY PAUL EDWARD;;THIBAULT PIERRE,,https://lens.org/139-037-609-554-186,Patent Application,yes,0,0,9,9,0,G01N33/6848;;G01N33/6848;;Y10T436/24;;Y10T436/24,G01N27/62;;B01J20/283;;G01N30/26;;G01N30/34;;G01N30/72;;G01N30/88;;G01N33/48;;G01N33/68,,0,0,,,,PENDING
35,EP,A2,EP 1446667 A2,173-217-674-826-687,2004-08-18,2004,EP 02799135 A,2002-11-13,IB 0205827 W;;US 33857801 P,2001-11-13,MASS INTENSITY PROFILING SYSTEM AND USES THEREOF,,CAPRION PHARMACEUTICALS INC,AGUILERA FRANK REINALDO MORALE;;FAUBERT DENIS;;BOULOS MARGUERITE;;TSANG JOHN SHING-CHUN;;HU MICHAEL;;OSTERMANN JOACHIM BERNHARD;;KEARNEY PAUL EDWARD;;THIBAULT PIERRE,,https://lens.org/173-217-674-826-687,Patent Application,yes,0,0,9,9,0,G01N33/6848;;G01N33/6848;;Y10T436/24;;Y10T436/24,G01N27/62;;B01J20/283;;G01N30/26;;G01N30/34;;G01N30/72;;G01N30/88;;G01N33/48;;G01N33/68,,1,0,,,See references of WO 03042774A3,DISCONTINUED
36,CA,A1,CA 2466837 A1,151-628-508-457-546,2003-05-22,2003,CA 2466837 A,2002-11-13,IB 0205827 W;;US 33857801 P,2001-11-13,MASS INTENSITY PROFILING SYSTEM AND USES THEREOF,"The present invention is directed to computer automated methods and systems for identifying and characterizing biomolecules in a biological sample. Mass spectrometry measurements are obtained on biomolecules in a sample. These measurements are analyzed to determine the abundance of the biomolecules in the sample, and the abundance measurements are couple with one or more distinguishing characteristics of biomolecules they are associated with, thereby permitting computer-mediated comparison of abundances of biomolecules from multiple biological samples.",CAPRION PHARMACEUTICALS INC,KEARNEY PAUL EDWARD;;THIBAULT PIERRE;;HU MICHAEL;;OSTERMANN JOACHIM BERNHARD;;AGUILERA FRANK REINALDO MORALE;;FAUBERT DENIS;;BOULOS MARGUERITE;;TSANG JOHN SHING-CHUN,,https://lens.org/151-628-508-457-546,Patent Application,no,0,0,9,9,0,G01N33/6848;;Y10T436/24;;Y10T436/24;;G01N33/6848,G01N27/62;;B01J20/283;;G01N30/26;;G01N30/34;;G01N30/72;;G01N30/88;;G01N33/48;;G01N33/68,,0,0,,,,DISCONTINUED
37,US,A1,US 2020/0033601 A1,101-357-739-373-416,2020-01-30,2020,US 201715823522 A,2017-11-27,US 201715823522 A,2017-11-27,HAPTIC SKULL CAP,"A haptic skull cap provides different types of haptic feedback to a user, which can be advantageous for providing a more immersive virtual reality experience. The haptic skull cap includes a fabric cap worn by a user. Physically attached to the fabric cap is a linear actuator that provides a focal impact to a user's forehead. Additionally, vibrational motors are physically attached to the fabric cap, where each vibration motor provides vibrational feedback to a different location of the user's head. The haptic skull cap can be worn by a user in conjunction with a head mounted display. Therefore, each type of haptic feedback provided by the haptic skull cap can be synchronized with the visual data stream provided by the head mounted display which further enhances the overall virtual reality experience for a user.",FACEBOOK TECH LLC,MAGRATH LESLEY RIBBLE;;HEWKO ADAM;;MILLER ROBIN MICHAEL;;DRINKWATER JARED I;;BLAND MICHAEL ROY;;ELLIS SHANE MICHAEL;;ZORNES PAUL MICHAEL;;JOHNSON BRADLEY MORRIS;;DOMBEY JOHN R;;BOULOS KHALED;;HIGGINS JASON,META PLATFORMS TECHNOLOGIES LLC (2017-12-06),https://lens.org/101-357-739-373-416,Patent Application,yes,3,11,1,1,0,G02B27/017;;G02B27/0176;;G06F1/163;;G06F1/163;;G06F3/011;;G06F3/012;;G06F3/016;;G06F3/016,G02B27/01;;G06F1/16;;G06F3/01,,0,0,,,,DISCONTINUED
38,WO,A3,WO 2006/116681 A3,012-038-797-732-443,2009-04-16,2009,US 2006/0016242 W,2006-04-28,US 67560305 P,2005-04-28,TAT-003 AND METHODS OF ASSESSING AND TREATING CANCER,"Surprisingly, the present inventors have discovered that expression of TAT-003 protein in human patients is associated with cancer, and that the over-expressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-003 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-003 expression or activity, comprising: contacting a candidate compound with a TAT-003 and detecting the presence or absence of binding between said compound and said TAT-003, or detecting a change in TAT-003 expression or activity. Methods are also included for the identification of compounds that modulate TAT-003 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-003 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.",CAPRION PHARMACEUTICALS INC;;HU MICHAEL;;TSANG JOHN;;JAITLY NAVDEEP;;SWAMY SAJANI;;HAMAIDI LYES;;FILGUEIRA MARCELO;;CHELSKY DANIEL;;LANOIX JOEL;;ENG KEVIN;;THIBAULT PIERRE;;FAUBERT DENIS;;BRUNET SYLVAIN;;OSTERMANN JOACHIM;;BOULOS MARGUERITE;;KEARNEY PAUL;;BUTLER HEATHER,HU MICHAEL;;TSANG JOHN;;JAITLY NAVDEEP;;SWAMY SAJANI;;HAMAIDI LYES;;FILGUEIRA MARCELO;;CHELSKY DANIEL;;LANOIX JOEL;;ENG KEVIN;;THIBAULT PIERRE;;FAUBERT DENIS;;BRUNET SYLVAIN;;OSTERMANN JOACHIM;;BOULOS MARGUERITE;;KEARNEY PAUL;;BUTLER HEATHER,,https://lens.org/012-038-797-732-443,Search Report,yes,1,0,2,2,0,G01N33/57419,G01N33/53;;C07K14/00,,0,0,,,,PENDING
39,WO,A2,WO 2006/116681 A2,034-366-784-288-524,2006-11-02,2006,US 2006/0016242 W,2006-04-28,US 67560305 P,2005-04-28,TAT-003 AND METHODS OF ASSESSING AND TREATING CANCER,"Surprisingly, the present inventors have discovered that expression of TAT-003 protein in human patients is associated with cancer, and that the over-expressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-003 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-003 expression or activity, comprising: contacting a candidate compound with a TAT-003 and detecting the presence or absence of binding between said compound and said TAT-003, or detecting a change in TAT-003 expression or activity. Methods are also included for the identification of compounds that modulate TAT-003 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-003 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.",CAPRION PHARMACEUTICALS INC;;HU MICHAEL;;TSANG JOHN;;JAITLY NAVDEEP;;SWAMI SAJANI;;HAMAIDI LYES;;FILGUEIRA MARCELO;;CHELSKY DANIEL;;LANOIX JOEL;;ENG KEVIN;;THIBAULT PIERRE;;FAUBERT DENIS;;BRUNET SYLVAIN;;OSTERMANN JOACHIM;;BOULOS MARGUERITE;;KEARNEY PAUL;;BUTLER HEATHER,HU MICHAEL;;TSANG JOHN;;JAITLY NAVDEEP;;SWAMI SAJANI;;HAMAIDI LYES;;FILGUEIRA MARCELO;;CHELSKY DANIEL;;LANOIX JOEL;;ENG KEVIN;;THIBAULT PIERRE;;FAUBERT DENIS;;BRUNET SYLVAIN;;OSTERMANN JOACHIM;;BOULOS MARGUERITE;;KEARNEY PAUL;;BUTLER HEATHER,,https://lens.org/034-366-784-288-524,Patent Application,yes,0,1,2,2,0,G01N33/57419,G01N33/574,,0,0,,,,PENDING
40,WO,A2,WO 2006/083957 A2,011-596-326-225-162,2006-08-10,2006,US 2006/0003543 W,2006-01-31,US 64875805 P,2005-01-31,TAT-001 AND METHODS OF ASSESSING AND TREATING CANCER,"Surprisingly, the present inventors have discovered that expression of TAT- 001 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-001 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-001 expression or activity, comprising: contacting a candidate compound with a TAT-001 and detecting the presence or absence of binding between said compound and said TAT-001, or detecting a change in TAT-001 expression or activity. Methods are also included for the identification of anti-cancer compounds and compounds that modulate TAT-001 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-001 expression or activity.",CAPRION PHARMACEUTICALS INC;;KEARNEY PAUL;;BUTLER HEATHER;;JAITLY NAVDEEP;;SWAMY SAJANI;;HAMAIDI LYES;;FILGUEIRA MARCELO;;THIBAULT PIERRE;;FAUBERT DENIS;;CHELSKY DANIEL;;LANOIX JOEL;;BRUNET SYLVAIN;;ENG KEVIN;;AGUILERA FRANK;;TSANG JOHN;;HU MICHAEL;;OSTERMANN JOACHIM;;BOULOS MARGUERITE,KEARNEY PAUL;;BUTLER HEATHER;;JAITLY NAVDEEP;;SWAMY SAJANI;;HAMAIDI LYES;;FILGUEIRA MARCELO;;THIBAULT PIERRE;;FAUBERT DENIS;;CHELSKY DANIEL;;LANOIX JOEL;;BRUNET SYLVAIN;;ENG KEVIN;;AGUILERA FRANK;;TSANG JOHN;;HU MICHAEL;;OSTERMANN JOACHIM;;BOULOS MARGUERITE,,https://lens.org/011-596-326-225-162,Patent Application,yes,0,0,3,3,0,C07K14/82;;C07K14/82;;C07K14/4748;;C07K14/4748;;C07K16/3046;;C07K16/3046,C07K16/30,,0,0,,,,PENDING
41,WO,A3,WO 2006/083957 A3,064-230-855-844-766,2009-04-09,2009,US 2006/0003543 W,2006-01-31,US 64875805 P,2005-01-31,TAT-001 AND METHODS OF ASSESSING AND TREATING CANCER,"Surprisingly, the present inventors have discovered that expression of TAT- 001 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-001 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-001 expression or activity, comprising: contacting a candidate compound with a TAT-001 and detecting the presence or absence of binding between said compound and said TAT-001, or detecting a change in TAT-001 expression or activity. Methods are also included for the identification of anti-cancer compounds and compounds that modulate TAT-001 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-001 expression or activity.",CAPRION PHARMACEUTICALS INC;;KEARNEY PAUL;;BUTLER HEATHER;;JAITLY NAVDEEP;;SWAMY SAJANI;;HAMAIDI LYES;;FILGUEIRA MARCELO;;THIBAULT PIERRE;;FAUBERT DENIS;;CHELSKY DANIEL;;LANOIX JOEL;;BRUNET SYLVAIN;;ENG KEVIN;;AGUILERA FRANK;;TSANG JOHN;;HU MICHAEL;;OSTERMANN JOACHIM;;BOULOS MARGUERITE,KEARNEY PAUL;;BUTLER HEATHER;;JAITLY NAVDEEP;;SWAMY SAJANI;;HAMAIDI LYES;;FILGUEIRA MARCELO;;THIBAULT PIERRE;;FAUBERT DENIS;;CHELSKY DANIEL;;LANOIX JOEL;;BRUNET SYLVAIN;;ENG KEVIN;;AGUILERA FRANK;;TSANG JOHN;;HU MICHAEL;;OSTERMANN JOACHIM;;BOULOS MARGUERITE,,https://lens.org/064-230-855-844-766,Search Report,yes,1,0,3,3,0,C07K14/82;;C07K14/82;;C07K14/4748;;C07K14/4748;;C07K16/3046;;C07K16/3046,C07K14/82;;C07K16/30;;C12P21/06,,0,0,,,,PENDING
42,US,A1,US 2007/0106065 A1,088-665-722-521-457,2007-05-10,2007,US 34493306 A,2006-01-31,US 34493306 A;;US 64875805 P,2005-01-31,TAT- 001 and methods of assessing and treating cancer,"Surprisingly, the present inventors have discovered that expression of TAT-001 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-001 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-001 expression or activity, comprising: contacting a candidate compound with a TAT-001 and detecting the presence or absence of binding between said compound and said TAT-001, or detecting a change in TAT-001 expression or activity. Methods are also included for the identification of anti-cancer compounds and compounds that modulate TAT-001 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-001 expression or activity.",CAPRION PHARMACEUTICALS INC,KEARNEY PAUL E;;BUTLER HEATHER;;JAITLY NAVDEEP;;SWAMY SAJANI;;HAMAIDI LYES;;FILGUEIRA MARCELO;;THIBAULT PIERRE;;FAUBERT DENIS;;CHELSKY DANIEL;;LANOIX JOEL;;BRUNET SYLVAIN;;ENG KEVIN;;AGUILERA FRANK R M;;TSANG JOHN S;;HU MICHAEL;;OSTERMANN JOACHIM B;;BOULOS MARGUERITE,,https://lens.org/088-665-722-521-457,Patent Application,yes,0,9,3,3,63,C07K14/82;;C07K14/82;;C07K14/4748;;C07K14/4748;;C07K16/3046;;C07K16/3046,C07K14/82;;A61K39/00;;A61K39/395;;C07K16/30;;C12P21/04;;C12P21/06;;C12P21/08,530/350;;530/388.8;;424/155.1;;424/185.1;;435/69.1;;435/320.1;;435/325;;435/70.21;;536/23.5,0,0,,,,DISCONTINUED
43,WO,A3,WO 2006/133145 A3,056-647-473-624-50X,2007-10-25,2007,US 2006/0021847 W,2006-06-06,US 68790105 P,2005-06-06,TAT-007 AND METHODS OF ASSESSING AND TREATING CANCER,"Surprisingly, the present inventors have discovered that expression of TAT- 007 protein in human patients is associated with cancer, and that the over-expressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-007 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-007 expression or activity, comprising: contacting a candidate compound with a TAT-007 and detecting the presence or absence of binding between said compound and said TAT-007, or detecting a change in TAT-007 expression or activity. Methods are also included for the identification of compounds that modulate TAT-007 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-007 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.",CAPRION PHARMACEUTICALS INC;;LANOIX JOEL;;ENG KEVIN;;THIBAULT PIERRE;;FAUBERT DENIS;;JAITLY NAVDEEP;;BRUNET SYLVAIN;;AGUILERA FRANK R M;;TSANG JOHN S-C;;HU MICHAEL;;OSTERMANN JOACHIM B;;BOULOS MARGUERITE;;KEARNEY PAUL E;;BUTLER HEATHER;;SWAMY SAJANI;;HAMAIDI LYES;;FILGUEIRA MARCELO;;CHELSKY DANIEL,LANOIX JOEL;;ENG KEVIN;;THIBAULT PIERRE;;FAUBERT DENIS;;JAITLY NAVDEEP;;BRUNET SYLVAIN;;AGUILERA FRANK R M;;TSANG JOHN S-C;;HU MICHAEL;;OSTERMANN JOACHIM B;;BOULOS MARGUERITE;;KEARNEY PAUL E;;BUTLER HEATHER;;SWAMY SAJANI;;HAMAIDI LYES;;FILGUEIRA MARCELO;;CHELSKY DANIEL,,https://lens.org/056-647-473-624-50X,Search Report,yes,1,0,2,2,0,G01N33/57484;;G01N2500/00,G01N33/53;;A61K38/00;;A61K39/395;;A61K48/00;;C07K5/00;;G01N33/577,,0,0,,,,PENDING
44,WO,A3,WO 2007/005559 A3,044-290-837-380-039,2009-04-16,2009,US 2006/0025483 W,2006-06-29,US 69556705 P,2005-06-30,TAT-005 AND METHODS OF ASSESSING AND TREATING CANCER,"Surprisingly, the present inventors have discovered that expression of TAT-005 protein in human patients is associated with cancer, and that the over-expressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-005 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer com\ pounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-005 expression or activity, comprising: contacting a candidate compound with a TAT-005 and detecting the presence or absence of binding between said compound and said TAT-005, or detecting a change in TAT-005 expression or activity. Methods are also included for the identification of compounds that modulate TAT-005 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-005 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.",CAPRION PHARMACEUTICALS INC;;FILGUEIRA MARCELO;;CHELSKY DANIEL;;LANOIX JOEL;;ENG KEVIN;;THIBAULT PIERRE;;FAUBERT DENIS;;JAITLY NAVDEEP;;BRUNET SYLVAIN;;AGUILERA FRANK R M;;TSANG JOHN S C;;HU MICHAEL;;OSTERMANN JOACHIM B;;BOULOS MARGUERITE;;KEARNEY PAUL E;;BUTLER HEATHER;;SWAMY SAJANI;;HAMAIDI LYES,FILGUEIRA MARCELO;;CHELSKY DANIEL;;LANOIX JOEL;;ENG KEVIN;;THIBAULT PIERRE;;FAUBERT DENIS;;JAITLY NAVDEEP;;BRUNET SYLVAIN;;AGUILERA FRANK R M;;TSANG JOHN S C;;HU MICHAEL;;OSTERMANN JOACHIM B;;BOULOS MARGUERITE;;KEARNEY PAUL E;;BUTLER HEATHER;;SWAMY SAJANI;;HAMAIDI LYES,,https://lens.org/044-290-837-380-039,Search Report,yes,2,0,3,3,0,A01K2217/05;;A01K2217/075;;C07K14/4748;;G01N33/57419;;G01N2500/04;;A61P35/04;;G01N33/57419;;C07K14/4748;;A01K2217/075;;G01N2500/04;;A01K2217/05,A61K38/00;;C12Q1/00;;A61K39/00;;A61K39/395;;A61K49/00;;C07H21/04;;C07K14/00;;C12Q1/68;;G01N33/53,,0,0,,,,PENDING
45,WO,A2,WO 2006/116541 A2,009-397-233-024-253,2006-11-02,2006,US 2006/0015904 W,2006-04-27,US 67519105 P;;US 67675205 P,2005-04-27,TAT-002 AND METHODS OF ASSESSING AND TREATING CANCER,"Surprisingly, the present inventors have discovered that expression of TAT-002 protein in human patients is associated with cancer, and that the over-expressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-002 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-002 expression or activity, comprising: contacting a candidate compound with a TAT-002 and detecting the presence or absence of binding between said compound and said TAT-002, or detecting a change in TAT-002 expression or activity. Methods are also included for the identification of compounds that modulate TAT-002 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-002 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.",CAPRION PHARMACEUTICALS INC;;BUTLER HEATHER;;SWAMY SAJANI;;HAMAIDI LYES;;FILGUEIRA MARCELO;;CHELSKY DANIEL;;LANOIX JOEL;;ENG KEVIN;;THIBAULT PIERRE;;FAUBERT DENIS;;JAITLY NAVDEEP;;BRUNET SYLVAIN;;AGUILERA FRANK R M;;TSANG JOHN S-C;;HU MICHAEL;;OSTERMANN JOACHIM B;;BOULOS MARGUERITE;;KEARNEY PAUL E,BUTLER HEATHER;;SWAMY SAJANI;;HAMAIDI LYES;;FILGUEIRA MARCELO;;CHELSKY DANIEL;;LANOIX JOEL;;ENG KEVIN;;THIBAULT PIERRE;;FAUBERT DENIS;;JAITLY NAVDEEP;;BRUNET SYLVAIN;;AGUILERA FRANK R M;;TSANG JOHN S-C;;HU MICHAEL;;OSTERMANN JOACHIM B;;BOULOS MARGUERITE;;KEARNEY PAUL E,,https://lens.org/009-397-233-024-253,Patent Application,yes,0,1,2,2,0,A61K38/00;;C07K14/47;;C07K16/30;;G01N33/57419;;G01N2500/00,G01N33/574,,0,0,,,,PENDING
46,US,A1,US 2010/0183630 A1,090-398-263-641-692,2010-07-22,2010,US 92288106 A,2006-06-29,US 92288106 A;;US 69556705 P;;US 2006/0025483 W,2005-06-30,Tat-005 and Methods of Assessing and Treating Cancer,"Surprisingly, the present inventors have discovered that expression of TAT-005 protein in human patients is associated with cancer, and that the over-expressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-005 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer com\ pounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-005 expression or activity, comprising: contacting a candidate compound with a TAT-005 and detecting the presence or absence of binding between said compound and said TAT-005, or detecting a change in TAT-005 expression or activity. Methods are also included for the identification of compounds that modulate TAT-005 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-005 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.",FILGUEIRA MARCELO;;CHELSKY DANIEL;;LANOIX JOEL;;ENG KEVIN;;THIBAULT PIERRE;;FAUBERT DENIS;;JAITLY NAVDEEP;;BRUNET SYLVAIN;;AGUILERA FRANK R M;;TSANG JOHN S-C;;HU MICHAEL;;OSTERMANN JOACHIM B;;BOULOS MARGUERITE;;KEARNEY PAUL E;;BUTLER HEATHER;;SWAMY SAJANI;;HAMAIDI LYES,FILGUEIRA MARCELO;;CHELSKY DANIEL;;LANOIX JOEL;;ENG KEVIN;;THIBAULT PIERRE;;FAUBERT DENIS;;JAITLY NAVDEEP;;BRUNET SYLVAIN;;AGUILERA FRANK R M;;TSANG JOHN S-C;;HU MICHAEL;;OSTERMANN JOACHIM B;;BOULOS MARGUERITE;;KEARNEY PAUL E;;BUTLER HEATHER;;SWAMY SAJANI;;HAMAIDI LYES,THALLION PHARMACEUTICALS INC (2007-03-13);;CAPRION PHARMACEUTICALS INC (2009-03-05),https://lens.org/090-398-263-641-692,Patent Application,yes,1,0,3,3,72,A01K2217/05;;A01K2217/075;;C07K14/4748;;G01N33/57419;;G01N2500/04;;A61P35/04;;G01N33/57419;;C07K14/4748;;A01K2217/075;;G01N2500/04;;A01K2217/05,C07K16/30;;A61K39/395;;A61P35/04;;C07K16/46;;G01N33/574,424/174.1;;530/387.1;;530/387.3;;530/389.7;;530/391.7;;530/391.3;;530/391.1;;435/7.23,0,0,,,,DISCONTINUED
47,WO,A3,WO 2006/116541 A3,061-702-544-550-940,2007-04-19,2007,US 2006/0015904 W,2006-04-27,US 67519105 P;;US 67675205 P,2005-04-27,TAT-002 AND METHODS OF ASSESSING AND TREATING CANCER,"Surprisingly, the present inventors have discovered that expression of TAT-002 protein in human patients is associated with cancer, and that the over-expressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-002 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-002 expression or activity, comprising: contacting a candidate compound with a TAT-002 and detecting the presence or absence of binding between said compound and said TAT-002, or detecting a change in TAT-002 expression or activity. Methods are also included for the identification of compounds that modulate TAT-002 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-002 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.",CAPRION PHARMACEUTICALS INC;;BUTLER HEATHER;;SWAMY SAJANI;;HAMAIDI LYES;;FILGUEIRA MARCELO;;CHELSKY DANIEL;;LANOIX JOEL;;ENG KEVIN;;THIBAULT PIERRE;;FAUBERT DENIS;;JAITLY NAVDEEP;;BRUNET SYLVAIN;;AGUILERA FRANK R M;;TSANG JOHN S-C;;HU MICHAEL;;OSTERMANN JOACHIM B;;BOULOS MARGUERITE;;KEARNEY PAUL E,BUTLER HEATHER;;SWAMY SAJANI;;HAMAIDI LYES;;FILGUEIRA MARCELO;;CHELSKY DANIEL;;LANOIX JOEL;;ENG KEVIN;;THIBAULT PIERRE;;FAUBERT DENIS;;JAITLY NAVDEEP;;BRUNET SYLVAIN;;AGUILERA FRANK R M;;TSANG JOHN S-C;;HU MICHAEL;;OSTERMANN JOACHIM B;;BOULOS MARGUERITE;;KEARNEY PAUL E,,https://lens.org/061-702-544-550-940,Search Report,yes,2,0,2,2,0,A61K38/00;;C07K14/47;;C07K16/30;;G01N33/57419;;G01N2500/00,C07K5/00;;A01K67/027;;A01N37/18;;A61K48/00;;C07H21/04;;C07K14/00;;C07K16/00;;C12N15/00;;C12N15/11;;C12Q1/68;;G01N33/53;;G01N33/574,,1,1,070-271-511-604-302,14665679;;pmc309050;;10.1128/mmbr.67.4.657-685.2003,"AGRAWAL N. ET AL.: ""RNA Interference: Biology, Mechanism, and Application"", MICRO MOL. BIOL. REV., vol. 67, 2003, pages 657 - 685, XP009030438",PENDING
48,WO,A2,WO 2006/133145 A2,151-292-854-382-640,2006-12-14,2006,US 2006/0021847 W,2006-06-06,US 68790105 P,2005-06-06,TAT-007 AND METHODS OF ASSESSING AND TREATING CANCER,"Surprisingly, the present inventors have discovered that expression of TAT- 007 protein in human patients is associated with cancer, and that the over-expressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-007 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-007 expression or activity, comprising: contacting a candidate compound with a TAT-007 and detecting the presence or absence of binding between said compound and said TAT-007, or detecting a change in TAT-007 expression or activity. Methods are also included for the identification of compounds that modulate TAT-007 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-007 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.",CAPRION PHARMACEUTICALS INC;;LANOIX JOEL;;ENG KEVIN;;THIBAULT PIERRE;;FAUBERT DENIS;;JAITLY NAVDEEP;;BRUNET SYLVAIN;;AGUILERA FRANK R M;;TSANG JOHN S-C;;HU MICHAEL;;OSTERMANN JOACHIM B;;BOULOS MARGUERITE;;KEARNEY PAUL E;;BUTLER HEATHER;;SWAMY SAJANI;;HAMAIDI LYES;;FILGUEIRA MARCELO;;CHELSKY DANIEL,LANOIX JOEL;;ENG KEVIN;;THIBAULT PIERRE;;FAUBERT DENIS;;JAITLY NAVDEEP;;BRUNET SYLVAIN;;AGUILERA FRANK R M;;TSANG JOHN S-C;;HU MICHAEL;;OSTERMANN JOACHIM B;;BOULOS MARGUERITE;;KEARNEY PAUL E;;BUTLER HEATHER;;SWAMY SAJANI;;HAMAIDI LYES;;FILGUEIRA MARCELO;;CHELSKY DANIEL,,https://lens.org/151-292-854-382-640,Patent Application,yes,0,1,2,2,0,G01N33/57484;;G01N2500/00,G01N33/574,,0,0,,,,PENDING
49,WO,A2,WO 2007/005559 A2,135-520-395-062-163,2007-01-11,2007,US 2006/0025483 W,2006-06-29,US 69556705 P,2005-06-30,TAT-005 AND METHODS OF ASSESSING AND TREATING CANCER,"Surprisingly, the present inventors have discovered that expression of TAT-005 protein in human patients is associated with cancer, and that the over-expressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-005 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer com\ pounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-005 expression or activity, comprising: contacting a candidate compound with a TAT-005 and detecting the presence or absence of binding between said compound and said TAT-005, or detecting a change in TAT-005 expression or activity. Methods are also included for the identification of compounds that modulate TAT-005 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-005 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.",CAPRION PHARMACEUTICALS INC;;FILGUEIRA MARCELO;;CHELSKY DANIEL;;LANOIX JOEL;;ENG KEVIN;;THIBAULT PIERRE;;FAUBERT DENIS;;JAITLY NAVDEEP;;BRUNET SYLVAIN;;AGUILERA FRANK R M;;TSANG JOHN S C;;HU MICHAEL;;OSTERMANN JOACHIM B;;BOULOS MARGUERITE;;KEARNEY PAUL E;;BUTLER HEATHER;;SWAMY SAJANI;;HAMAIDI LYES,FILGUEIRA MARCELO;;CHELSKY DANIEL;;LANOIX JOEL;;ENG KEVIN;;THIBAULT PIERRE;;FAUBERT DENIS;;JAITLY NAVDEEP;;BRUNET SYLVAIN;;AGUILERA FRANK R M;;TSANG JOHN S C;;HU MICHAEL;;OSTERMANN JOACHIM B;;BOULOS MARGUERITE;;KEARNEY PAUL E;;BUTLER HEATHER;;SWAMY SAJANI;;HAMAIDI LYES,,https://lens.org/135-520-395-062-163,Patent Application,yes,0,1,3,3,0,A01K2217/05;;A01K2217/075;;C07K14/4748;;G01N33/57419;;G01N2500/04;;A61P35/04;;G01N33/57419;;C07K14/4748;;A01K2217/075;;G01N2500/04;;A01K2217/05,G01N33/574,,0,0,,,,PENDING
